CONTENTS:
• Buprenorphine in the treatment of heroin addiction: Déjà vu all over again. Stimmel B., p. 1-2.
• The emerging buprenorphine epidemic in the United States. Wish E.D., Artigiani E., Billing A., Hauser W., Hemberg J., Shiplet M., et al., p. 3-7.
• Effect of buprenorphine dose on treatment outcome. Fareed A., Vayalapalli S., Casarella J., Drexler K., p. 8-18.
• Substance use during pregnancy and postnatal outcomes. Irner T.B., Teasdale T.W., Nielsen T., Vedal S., Olofsson M., p. 19-28.
• Cognitive and social development in preschool children born to women using substances. Irner T.B., Teasdale T.W., Olofsson M., p. 29-44.
• Addiction in developmental perspective: influence of conduct disorder severity, subtype, and attention-deficit hyperactivity disorder on problem severity and comorbidity in adults with opioid dependence. Carpentier P.J., Knapen L.J., van Gogh M.T., Buitelaar J.K., De Jong C.A., p. 45-59.
• Comparison of substance use milestones in cannabis- and cocaine-dependent patients. Horey J.T., Mariani J.J., Cheng W.Y., Bisaga A., Sullivan M., Nunes E., et al., p. 60-66.
• Sleep and gambling severity in a community sample of gamblers. Parhami I., Siani A., Rosenthal R.J., Lin S., Collard M., Fong T.W., p. 67-79.
• Assessment of risky injection practices associated with hepatitis B, hepatitis C, and human immunodeficiency virus and using the blood-borne virus transmission risk assessment questionnaire. Reynolds G.L., Fisher D.G., Napper L.E., p. 80-88.